Latest News
Maze Therapeutics, Inc.
- Is Maze Therapeutics (MAZE) Undervalued Or Is Its Recent Rebound Already Priced In?
- Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential
- Form 4 Maze Therapeutics Inc: Jason V. Coloma (Director, CEO) For: 1 October
- Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares
- Maze Therapeutics Q2 2026 Earnings: Slight EPS Miss Fails to Dislodge a Modest Stock Gain - Annual Earnings Summary
- Maze Therapeutics Q2 2026 Earnings: Slight EPS Miss Fails to Dislodge a Modest Stock Gain - Post-Earnings Drift
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
- Maze Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Reports No Top-Line Revenue - Guidance Revision Trend
- Two trusts sold 31,908 and 2,593 shares under Maze Therapeutics (MAZE) CEO Jason V. Coloma’s trading plan.
- An officer plans to sell 16,141 Maze Therapeutics (MAZE) shares on October 1, 2026.
Headlines from the last 30 days, linking to the original publishers. See all market news →